Full text is available at the source.
Abstract
Lipid nanoparticles have shown early clinical successes in mRNA therapeutics but face limitations in liver biodistribution and systemic tolerability.
- Polymeric delivery systems may provide a flexible alternative to lipid nanoparticles for mRNA therapeutics.
- Tunable properties of polymeric systems allow for precise control over mRNA protection and targeting.
- Recent advancements include structural modifications and stimuli-responsive designs that may enhance stability and reduce toxicity.
- High-throughput screening of polymers is associated with improved organ- or cell-specific delivery.
- Challenges such as immunogenicity and manufacturing scalability need to be addressed for the effective application of these systems.
Simplified